Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Effects of rosiglitazone treatment on lipid composition (Study ST000675)

C18 NEGATIVE ION MODE (Analysis AN001036)

Metabolite	Structure	F1	F2
lysoPE 20:4; [M-H]-@1.28	ME186714	1.03	0.97
PE 38:3; [M-H]-@7.17	ME186669	1.01	0.99
PA 34:2; [M-H]-@6.18	ME186623	1.06	0.94
FFA(20:4) Arachidonic acid	ME186614	1.09	0.91
PE 35:4; [M-H]-@5.98	ME186661	1.09	0.91
PC 38:7; [M-Ac-H]-@5.45	ME186649	0.64	1.36
PC 40:7; [M-Ac-H]-@6.11	ME186652	0.63	1.37
PS 40:2; [M-H]-@7.26	ME186707	0.81	1.19
PI 36:3; [M-H]-@5.48	ME186691	0.81	1.19
PG 36:1; [M-H]-@6.55	ME186681	0.81	1.19
PE 37:4; [M-H]-@6.62	ME186667	0.81	1.19
PE 34:1; [M-H]-@6.76	ME186656	0.81	1.19
FFA(18:1)	ME186609	0.81	1.19
PC 34:3; [M-Ac-H]-@5.66	ME186635	0.81	1.19
PC 35:3; [M-Ac-H]-@6.01	ME186638	0.82	1.18
PE 36:5; [M-H]-@5.90	ME186666	0.82	1.18
PS 40:5; [M-H]-@6.15	ME186709	0.80	1.20
plasmenyl-PE 33:1; [M-H]-@6.83	ME186716	0.80	1.20
PI 34:2; [M-H]-@5.32	ME186689	0.80	1.20
FFA(18:2)	ME186610	0.80	1.20
PE 38:1; [M-H]-@7.84	ME186668	0.80	1.20
PS 34:1; [M-H]-@5.88	ME186697	0.79	1.21
PI 38:4; [M-H]-@5.94	ME186693	0.79	1.21
PG 38:4; [M-H]-@5.51	ME186685	0.79	1.21
PE 34:3; [M-H]-@5.87	ME186658	0.79	1.21
PE 30:0; [M-H]-@6.02	ME186654	0.79	1.21
PC 38:2; [M-Ac-H]-@7.30	ME186645	0.79	1.21
PC 40:5; [M-Ac-H]-@6.97	ME186651	0.79	1.21
PS 38:4; [M-H]-@6.06	ME186704	0.77	1.23
PI 38:5; [M-H]-@5.47	ME186694	0.78	1.22
PG 36:2; [M-H]-@6.02	ME186682	0.78	1.22
PE 32:2; [M-H]-@5.64	ME186655	0.78	1.22
PG 34:1; [M-H]-@5.91	ME186678	0.78	1.22
lysoPE 18:0; [M-H]-@2.40	ME186711	0.76	1.24
PI 36:2; [M-H]-@5.94	ME186690	0.76	1.24
PC 30:1; [M-Ac-H]-@5.32	ME186626	0.75	1.25
PI 32:1; [M-H]-@5.15	ME186687	0.75	1.25
PS 36:3; [M-H]-@5.64	ME186701	0.74	1.26
PC 37:4; [M-Ac-H]-@6.42	ME186644	0.74	1.26
PS 36:2; [M-H]-@6.02	ME186700	0.74	1.26
FFA(22:2)	ME186617	0.72	1.28
PS 38:5; [M-H]-@5.59	ME186705	0.73	1.27
PG 32:1; [M-H]-@5.36	ME186676	0.73	1.27
PC 36:5; [M-Ac-H]-@5.57	ME186643	0.73	1.27
PE 40:2; [M-H]-@7.88	ME186672	0.73	1.27
PG 33:0; [M-H]-@6.15	ME186677	0.71	1.29
FFA(20:2)	ME186613	0.70	1.30
PE 36:2; [M-H]-@5.99	ME186664	0.70	1.30
FFA(22:3)	ME186618	0.67	1.33
FFA(20:1)	ME186612	0.69	1.31
PG 34:2; [M-H]-@5.32	ME186679	0.68	1.32
lysoPE 18:2; [M-H]-@1.29	ME186713	0.95	1.05
PC 35:1; [M-Ac-H]-@6.91	ME186636	0.93	1.07
PG 40:5; [M-H]-@5.75	ME186686	0.94	1.06
PE 40:1; [M-H]-@8.32	ME186671	0.94	1.06
PC 34:1; [M-Ac-H]-@6.58	ME186633	0.94	1.06
FFA(24:3)	ME186622	0.94	1.06
FFA(16:0)	ME186607	0.94	1.06
FFA(22:0)	ME186615	0.94	1.06
PC 36:1; [M-Ac-H]-@7.19	ME186639	0.98	1.02
PC 40:8; [M-Ac-H]-@5.70	ME186653	0.98	1.02
FFA(18:0)	ME186608	0.97	1.03
PC 33:2; [M-Ac-H]-@5.86	ME186632	0.97	1.03
PC 33:1; [M-Ac-H]-@6.33	ME186631	0.96	1.04
PC 31:0; [M-Ac-H]-@6.14	ME186627	0.96	1.04
PC 32:0; [M-Ac-H]-@6.49	ME186628	0.96	1.04
plasmenyl-PE 36:2; [M-H]-@6.50	ME186719	0.89	1.11
plasmenyl-PE 34:3; [M-H]-@6.24	ME186718	0.89	1.11
PI 34:1; [M-H]-@5.81	ME186688	0.89	1.11
PE 40:6; [M-H]-@6.85	ME186674	0.89	1.11
PE 35:2; [M-H]-@6.58	ME186660	0.89	1.11
lysoPE 18:1; [M-H]-@1.78	ME186712	0.89	1.11
PC 34:2; [M-Ac-H]-@6.13	ME186634	0.89	1.11
PS 38:6; [M-H]-@5.33	ME186706	0.90	1.10
plasmenyl-PE 36:3; [M-H]-@6.78	ME186720	0.90	1.10
PE 36:1; [M-H]-@6.79	ME186662	0.90	1.10
PE 35:1; [M-H]-@7.07	ME186659	0.90	1.10
PC 36:4; [M-Ac-H]-@6.02	ME186642	0.90	1.10
PC 38:4; [M-Ac-H]-@6.68	ME186647	0.90	1.10
PS 32:1; [M-H]-@5.26	ME186696	0.92	1.08
plasmenyl-PE 38:1; [M-H]-@8.10	ME186721	0.92	1.08
PC 28:0; [M-Ac-H]-@5.15	ME186624	0.92	1.08
FFA(20:0)	ME186611	0.92	1.08
FFA(24:0)	ME186619	0.92	1.08
PG 36:0; [M-H]-@6.97	ME186680	0.91	1.09
PE 34:2; [M-H]-@6.31	ME186657	0.91	1.09
PE 38:4; [M-H]-@6.89	ME186670	0.91	1.09
PS 40:6; [M-H]-@5.97	ME186710	0.83	1.17
PG 36:3; [M-H]-@5.39	ME186683	0.83	1.17
PC 32:1; [M-Ac-H]-@5.98	ME186629	0.83	1.17
PE 36:1; [M-H]-@7.35	ME186663	0.83	1.17
PS 36:1; [M-H]-@6.53	ME186699	0.84	1.16
PS 34:2; [M-H]-@5.44	ME186698	0.84	1.16
plasmenyl-PE 38:2; [M-H]-@7.71	ME186722	0.84	1.16
plasmenyl-PE 34:2; [M-H]-@6.63	ME186717	0.84	1.16
PC 38:3; [M-Ac-H]-@6.95	ME186646	0.84	1.16
lysoPE 22:5; [M-H]-@1.49	ME186715	0.84	1.16
CL 78:3; [M-2H](2-)@7.45	ME186606	0.84	1.16
FFA(22:1)	ME186616	0.84	1.16
PS 36:4; [M-H]-@5.42	ME186702	0.85	1.15
PC 36:3; [M-Ac-H]-@6.29	ME186641	0.85	1.15
FFA(24:1)	ME186620	0.85	1.15
PC 35:2; [M-Ac-H]-@6.46	ME186637	0.85	1.15
PS 38:3; [M-H]-@6.29	ME186703	0.86	1.14
PI 40:5; [M-H]-@6.02	ME186695	0.86	1.14
PG 38:3; [M-H]-@5.91	ME186684	0.86	1.14
PC 32:2; [M-Ac-H]-@5.48	ME186630	0.86	1.14
PE 40:7; [M-H]-@6.33	ME186675	0.86	1.14
plasmenyl-PE 40:5; [M-H]-@7.29	ME186723	0.88	1.12
PE 40:5; [M-H]-@6.91	ME186673	0.88	1.12
PC 40:4; [M-Ac-H]-@7.19	ME186650	0.88	1.12
PC 36:2; [M-Ac-H]-@6.72	ME186640	0.88	1.12
FFA(24:2)	ME186621	0.88	1.12
PC 30:0; [M-Ac-H]-@5.87	ME186625	0.88	1.12
PS 40:4; [M-H]-@6.48	ME186708	0.87	1.13
PI 36:4; [M-H]-@5.36	ME186692	0.87	1.13
PC 38:5; [M-Ac-H]-@6.26	ME186648	0.87	1.13
PE 36:3; [M-H]-@6.48	ME186665	0.87	1.13

Factors:

F1	TYPE:control
F2	TYPE:Rosi

Data matrix